blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2322175

EP2322175 - PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTENSION AND METABOLIC SYNDROME AND USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.04.2018
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  05.05.2017
FormerGrant of patent is intended
Status updated on  03.01.2017
Most recent event   Tooltip29.05.2020Lapse of the patent in a contracting state
New state(s): PT		published on 01.07.2020  [2020/27]
Applicant(s)For all designated states
Lunan Pharmaceutical Group Corporation
No. 209, Hongqi Road
Linyi City
Shandong Province 276006 / CN
[2017/23]
Former [2011/20]For all designated states
Lunan Pharmaceutical Group Corporation
No. 209, Hongqi Road Linyi City
Shandong Province 276006 / CN
Inventor(s)01 / ZHAO, Zhiquan
Dormitory of Lunan Pharmaceuticals Factory
Xiduan Beice
Hongqi Road
Linyi
Shandong 276005 / CN
 [2017/23]
Former [2011/20]01 / ZHAO, Zhiquan
Dormitory of Lunan Pharmaceuticals Factory Xiduan Beice Hongqi Road Linyi
Shandong 276005 / CN
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2017/23]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2013/37]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham
NG1 5GG / GB
Former [2011/20]Crowhurst, Charlotte Waveney
Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham
NG1 5DD / GB
Application number, filing date09799934.623.07.2009
[2011/20]
WO2009CN00823
Priority number, dateCN20081013375724.07.2008         Original published format: CN200810133757
[2011/20]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010009618
Date:28.01.2010
Language:ZH
[2010/04]
Type: A1 Application with search report 
No.:EP2322175
Date:18.05.2011
Language:EN
[2011/20]
Type: B1 Patent specification 
No.:EP2322175
Date:07.06.2017
Language:EN
[2017/23]
Search report(s)International search report - published on:CN28.01.2010
(Supplementary) European search report - dispatched on:EP24.10.2011
ClassificationIPC:A61K31/4178, A61K31/4184, A61K31/519, A61K31/41, A61K45/06, A61K31/4439, A61K31/505, A61K9/20, A61K9/48, A61K9/14, A61P9/12, A61P3/00, A61P3/06, A61P3/10, A61K9/16, A61K9/00
[2011/47]
CPC:
A61K9/4866 (EP,US); A61K31/4178 (EP,KR,US); A61K31/41 (EP,US);
A61K31/4184 (EP,KR,US); A61K31/4439 (EP,US); A61K31/505 (EP,US);
A61K31/519 (EP,KR,US); A61K45/06 (EP,US); A61K9/0056 (EP,US);
A61K9/1623 (EP,US); A61K9/1652 (EP,US); A61K9/20 (EP,US);
A61K9/2027 (EP,US); A61K9/2054 (EP,US); A61K9/2059 (EP,US);
A61K9/209 (EP,US); A61K9/485 (EP,US); A61P13/12 (EP);
A61P19/06 (EP); A61P3/00 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/08 (EP); A61P3/10 (EP);
A61P9/10 (EP); A61P9/12 (EP) (-)
C-Set:
A61K31/4178, A61K2300/00 (US,EP);
A61K31/4184, A61K2300/00 (US,EP);
A61K31/41, A61K2300/00 (EP,US);
A61K31/4439, A61K2300/00 (US,EP);
A61K31/505, A61K2300/00 (EP,US);
A61K31/519, A61K2300/00 (EP,US)
(-)
Former IPC [2011/20]A61K31/4178, A61K31/4184, A61K31/519, A61K31/41, A61K45/06, A61K31/4439, A61K31/505, A61K9/20, A61K9/48, A61K9/14, A61P9/12, A61P3/00, A61P3/06, A61P3/10
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2017/23]
Former [2011/20]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON HYPERTONIE UND METABOLISCHEM SYNDROM UND IHRE ANWENDUNG[2011/20]
English:PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTENSION AND METABOLIC SYNDROME AND USE THEREOF[2011/20]
French:COMPOSITION PHARMACEUTIQUE POUR TRAITER L HYPERTENSION ET LE SYNDROME MÉTABOLIQUE ET UTILISATION DE CELLE-CI[2011/20]
Entry into regional phase18.02.2011Translation filed 
18.02.2011National basic fee paid 
18.02.2011Search fee paid 
18.02.2011Designation fee(s) paid 
18.02.2011Examination fee paid 
Examination procedure18.02.2011Examination requested  [2011/20]
19.04.2012Amendment by applicant (claims and/or description)
10.02.2014Despatch of a communication from the examining division (Time limit: M04)
06.06.2014Reply to a communication from the examining division
08.06.2016Despatch of a communication from the examining division (Time limit: M04)
27.09.2016Reply to a communication from the examining division
04.01.2017Communication of intention to grant the patent
27.04.2017Fee for grant paid
27.04.2017Fee for publishing/printing paid
27.04.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.02.2014
Opposition(s)08.03.2018No opposition filed within time limit [2018/20]
Fees paidRenewal fee
12.07.2011Renewal fee patent year 03
13.07.2012Renewal fee patent year 04
10.07.2013Renewal fee patent year 05
14.07.2014Renewal fee patent year 06
29.07.2015Renewal fee patent year 07
19.07.2016Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.07.2009
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
MK07.06.2017
NL07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
IE23.07.2017
LU23.07.2017
MT23.07.2017
BE31.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
[2020/27]
Former [2020/15]HU23.07.2009
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
MK07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
IE23.07.2017
LU23.07.2017
MT23.07.2017
BE31.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2019/51]HU23.07.2009
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
MK07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
IE23.07.2017
LU23.07.2017
MT23.07.2017
BE31.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2019/46]HU23.07.2009
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
IE23.07.2017
LU23.07.2017
MT23.07.2017
BE31.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2019/31]HU23.07.2009
AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
IE23.07.2017
LU23.07.2017
MT23.07.2017
BE31.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/43]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
IE23.07.2017
LU23.07.2017
MT23.07.2017
BE31.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/39]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
IE23.07.2017
LU23.07.2017
BE31.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/34]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
IE23.07.2017
LU23.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/23]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
IE23.07.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/21]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
CH31.07.2017
LI31.07.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/18]AT07.06.2017
CZ07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/11]AT07.06.2017
CZ07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/10]AT07.06.2017
CZ07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
RO07.06.2017
SE07.06.2017
SK07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2018/09]EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/52]FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/50]FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/49]FI07.06.2017
HR07.06.2017
LT07.06.2017
NO07.09.2017
GR08.09.2017
Documents cited:Search[XP]CN101229372  ;
 [XP]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2008, no. 77, Database accession no. 2008-N03484, XP002660765 & CN101229372 A 20080730 (LUNAN PHARM GROUP CORP) [XP] 1-11 * abstract *
 [A]  - NAOUMOVA ET AL, "Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, (20071105), vol. 50, no. 21, doi:10.1016/J.JACC.2007.07.070, ISSN 0735-1097, pages 2051 - 2058, XP022418186 [A] 1-11 * abstract * * table 1 * * Discussion *

DOI:   http://dx.doi.org/10.1016/j.jacc.2007.07.070
International search[XP]CN101229372  (LUNAN PHARM GROUP CORP [CN]);
 [A]  - WU GUANHUI ET AL., "Metabolic Syndrome and Ischemic Cerebrovascular.", CEREBROVASC DIS FOREIGN MED SCI (CHINESE), (20050515), vol. 13, no. 5, pages 360 - 363, XP008143176
 [AP]  - ZHANG JIDONG ET AL., "Progress of Blood Pressure Lowermg Drugs not Considered Antihypertensives.", ADV CARDIOVASC DIS (CHINESE), (200811), vol. 29, no. 6, pages 953 - 956, XP008143315
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.